HomeCompareMEIP vs JEPQ

MEIP vs JEPQ: Dividend Comparison 2026

MEIP yields 65.15% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MEIP wins by $791.1K in total portfolio value
10 years
MEIP
MEIP
● Live price
65.15%
Share price
$3.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$835.9K
Annual income
$207,949.71
Full MEIP calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — MEIP vs JEPQ

📍 MEIP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMEIPJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MEIP + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MEIP pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MEIP
Annual income on $10K today (after 15% tax)
$5,537.46/yr
After 10yr DRIP, annual income (after tax)
$176,757.25/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, MEIP beats the other by $174,927.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MEIP + JEPQ for your $10,000?

MEIP: 50%JEPQ: 50%
100% JEPQ50/50100% MEIP
Portfolio after 10yr
$440.3K
Annual income
$105,051.15/yr
Blended yield
23.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MEIP right now

MEIP
Analyst Ratings
10
Buy
7
Hold
1
Sell
Consensus: Buy
Altman Z
2.5
Piotroski
2/9
JEPQ
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MEIP buys
0
JEPQ buys
0
No recent congressional trades found for MEIP or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMEIPJEPQ
Forward yield65.15%11.10%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$835.9K$44.8K
Annual income after 10y$207,949.71$2,152.59
Total dividends collected$703.6K$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: MEIP vs JEPQ ($10,000, DRIP)

YearMEIP PortfolioMEIP Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$17,215$6,514.66$11,930$1,110.39+$5.3KMEIP
2$28,901$10,481.08$14,133$1,224.34+$14.8KMEIP
3$47,369$16,444.98$16,632$1,340.46+$30.7KMEIP
4$75,875$25,190.26$19,454$1,457.97+$56.4KMEIP
5$118,896$37,709.83$22,626$1,576.08+$96.3KMEIP
6$182,444$55,225.52$26,175$1,694.09+$156.3KMEIP
7$274,414$79,198.88$30,133$1,811.32+$244.3KMEIP
8$404,953$111,329.87$34,531$1,927.17+$370.4KMEIP
9$586,841$153,541.60$39,403$2,041.08+$547.4KMEIP
10$835,870$207,949.71$44,787$2,152.59+$791.1KMEIP

MEIP vs JEPQ: Complete Analysis 2026

MEIPStock

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Full MEIP Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this MEIP vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MEIP vs SCHDMEIP vs JEPIMEIP vs OMEIP vs KOMEIP vs MAINMEIP vs XYLDMEIP vs QYLDMEIP vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.